Resources from the same session
2111 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Daniel Shao Weng Tan
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract